Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial
JL Vincent, B Francois, I Zabolotskikh, MK Daga… - Jama, 2019 - jamanetwork.com
Importance Previous research suggested that soluble human recombinant thrombomodulin
may reduce mortality among patients with sepsis-associated coagulopathy. Objective To
determine the effect of human recombinant thrombomodulin vs placebo on 28-day all-cause
mortality among patients with sepsis-associated coagulopathy. Design, Setting, and
Participants The SCARLET trial was a randomized, double-blind, placebo-controlled,
multinational, multicenter phase 3 study conducted in intensive care units at 159 sites in 26 …
may reduce mortality among patients with sepsis-associated coagulopathy. Objective To
determine the effect of human recombinant thrombomodulin vs placebo on 28-day all-cause
mortality among patients with sepsis-associated coagulopathy. Design, Setting, and
Participants The SCARLET trial was a randomized, double-blind, placebo-controlled,
multinational, multicenter phase 3 study conducted in intensive care units at 159 sites in 26 …